JP Morgan Chase
TEVA icon

JP Morgan Chase’s Teva Pharmaceuticals TEVA Stock Holding History

JP Morgan Chase’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.55M Sell
54,600
-1,168,800
-96% -$37.6M ﹤0.01% 4291
2025
Q4 		$38.2M Buy
1,223,400
+285,600
+30% +$7.04M ﹤0.01% 1549
2025
Q3 		$18.9M Buy
937,800
+466,100
+99% +$8.19M ﹤0.01% 2145
2025
Q2 		$7.91M Sell
471,700
-200,000
-30% -$3.23M ﹤0.01% 2756
2025
Q1 		$10.3M Sell
671,700
-1,618,400
-71% -$28.9M ﹤0.01% 2524
2024
Q4 		$50.5M Sell
2,290,100
-1,978,000
-46% -$36M ﹤0.01% 1323
2024
Q3 		$76.9M Buy
4,268,100
+924,000
+28% +$16.2M 0.01% 1084
2024
Q2 		$54.3M Buy
+3,344,100
New +$51.5M ﹤0.01% 1202
2023
Q2 		– Sell
-256,900
Closed -$2.27M – 7325
2023
Q1 		$2.27M Buy
+256,900
New +$2.54M ﹤0.01% 3454
2022
Q4 		– Sell
-21,500
Closed -$174K – 6993
2022
Q3 		$174K Buy
+21,500
New +$190K ﹤0.01% 5019
2022
Q1 		– Sell
-385,700
Closed -$3.09M – 7011
2021
Q4 		$3.09M Sell
385,700
-735,600
-66% -$6.64M ﹤0.01% 3470
2021
Q3 		$10.9M Buy
1,121,300
+3,800
+0.3% +$35.6K ﹤0.01% 2308
2021
Q2 		$11.1M Sell
1,117,500
-77,600
-6% -$821K ﹤0.01% 2345
2021
Q1 		$13.8M Sell
1,195,100
-229,000
-16% -$2.63M ﹤0.01% 2070
2020
Q4 		$13.7M Sell
1,424,100
-254,900
-15% -$2.44M ﹤0.01% 1940
2020
Q3 		$14.9M Buy
1,679,000
+555,000
+49% +$5.87M ﹤0.01% 1710
2020
Q2 		$13.9M Hold
1,124,000
– – ﹤0.01% 1654
2020
Q1 		$10.1M Sell
1,124,000
-6,159,200
-85% -$63.1M ﹤0.01% 1734
2019
Q4 		$71.4M Buy
7,283,200
+132,900
+2% +$1.19M 0.01% 793
2019
Q3 		$49.2M Sell
7,150,300
-1,270,000
-15% -$9.73M 0.01% 958
2019
Q2 		$76.5M Buy
8,420,300
+2,442,800
+41% +$29.5M 0.01% 772
2019
Q1 		$93.7M Buy
+5,977,500
New +$105M 0.02% 670
2018
Q2 		– Sell
-500,000
Closed -$8.54M – 5695
2018
Q1 		$8.54M Sell
500,000
-630,000
-56% -$12.3M ﹤0.01% 2135
2017
Q4 		$21.4M Buy
1,130,000
+1,115,000
+7,433% +$16.8M ﹤0.01% 1519
2017
Q3 		$257K Sell
15,000
-160,000
-91% -$3.6M ﹤0.01% 4036
2017
Q2 		$5.81M Sell
175,000
-125,000
-42% -$3.87M ﹤0.01% 2375
2017
Q1 		$9.63M Buy
+300,000
New +$10.2M ﹤0.01% 1961
2016
Q4 		– Sell
-30,481
Closed -$1.4M – 5128
2016
Q3 		$1.4M Sell
30,481
-119,519
-80% -$6.24M ﹤0.01% 2980
2016
Q2 		$7.53M Buy
+150,000
New +$7.99M ﹤0.01% 2023
2016
Q1 		– Sell
-52,700
Closed -$3.46M – 4933
2015
Q4 		$3.46M Buy
52,700
+52,000
+7,429% +$3.21M ﹤0.01% 2446
2015
Q3 		$40K Sell
700
-245,500
-100% -$15.9M ﹤0.01% 3803
2015
Q2 		$14.6M Sell
246,200
-190,800
-44% -$11.8M ﹤0.01% 1632
2015
Q1 		$27.2M Buy
437,000
+408,200
+1,417% +$23.7M 0.01% 1227
2014
Q4 		$1.66M Buy
+28,800
New +$1.6M ﹤0.01% 3070
2014
Q1 		– Sell
-800
Closed -$32K – 3918
2013
Q4 		$32K Sell
800
-100
-11% -$3.94K ﹤0.01% 3994
2013
Q3 		$34K Sell
900
-37,700
-98% -$1.47M ﹤0.01% 4289
2013
Q2 		$1.51M Buy
+38,600
New +$1.5M ﹤0.01% 2991

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase's TEVA Position: Q1 2026 in Review

JP Morgan Chase increased its Teva Pharmaceuticals (TEVA) stake by 466% in Q1 2026, buying an estimated $179M and bringing the position to 6,762,744 shares worth $192M. The position accounts for 0.01% of the portfolio, ranked #712.

JP Morgan Chase first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $492M in Q3 2016. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • JP Morgan Chase held 6,762,744 shares of Teva Pharmaceuticals worth $192M as of Q1 2026.
  • JP Morgan Chase bought 5,568,294 Teva Pharmaceuticals shares in Q1 2026, an estimated $179M.
  • Teva Pharmaceuticals made up 0.01% of JP Morgan Chase's portfolio in Q1 2026, its #712 holding.
  • JP Morgan Chase first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • JP Morgan Chase's Teva Pharmaceuticals position peaked at $492M in Q3 2016.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.